See more : Huntington Ingalls Industries, Inc. (HII) Income Statement Analysis – Financial Results
Complete financial analysis of Leap Therapeutics, Inc. (LPTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Leap Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Transmissora Aliança de Energia Elétrica S.A. (TAEE4.SA) Income Statement Analysis – Financial Results
- The Japan Steel Works, Ltd. (JPSWY) Income Statement Analysis – Financial Results
- Gander Gold Corporation (GAND.CN) Income Statement Analysis – Financial Results
- GK Software SE (GKS.HM) Income Statement Analysis – Financial Results
- Center International Group Co.,Ltd. (603098.SS) Income Statement Analysis – Financial Results
Leap Therapeutics, Inc. (LPTX)
About Leap Therapeutics, Inc.
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 1.50M | 1.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 427.00K | 415.00K | 0.00 | 0.00 | 776.00K | 49.00K | 48.00K | 25.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -427.00K | -415.00K | 1.50M | 1.50M | -776.00K | -49.00K | -48.00K | -25.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 73.23M | 44.97M | 32.16M | 20.42M | 24.37M | 21.07M | 22.50M | 23.29M | 15.37M | 15.54M | 9.30M | 7.17M |
| General & Administrative | 13.81M | 11.80M | 10.77M | 9.62M | 9.09M | 8.92M | 9.85M | 4.23M | 5.72M | 4.71M | 4.57M | 1.51M |
| Selling & Marketing | -427.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.38M | 11.80M | 10.77M | 9.62M | 9.09M | 8.92M | 9.85M | 4.23M | 5.72M | 4.71M | 4.57M | 1.51M |
| Other Expenses | 0.00 | -2.05M | -1.23M | -231.00K | -132.00K | 756.00K | 0.00 | 3.12M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 87.04M | 54.71M | 41.70M | 29.81M | 33.32M | 30.00M | 32.35M | 27.52M | 21.09M | 20.25M | 13.87M | 8.68M |
| Cost & Expenses | 87.04M | 54.71M | 41.70M | 29.81M | 33.32M | 30.00M | 32.35M | 27.52M | 21.09M | 20.25M | 13.87M | 8.68M |
| Interest Income | 4.03M | 925.00K | 9.00K | 93.00K | 313.00K | 447.00K | 170.00K | 2.00K | 156.00K | 40.00K | 94.00K | 102.00K |
| Interest Expense | 0.00 | 54.00K | 41.00K | 39.00K | 23.00K | 19.00K | 121.00K | 1.23M | 18.00K | 4.37M | 0.00 | 0.00 |
| Depreciation & Amortization | 427.00K | 415.00K | 556.00K | 668.00K | 776.00K | 49.00K | 48.00K | 25.00K | 474.00K | 657.00K | 640.00K | 649.00K |
| EBITDA | -80.99M | -53.98M | -40.01M | -26.81M | -32.10M | -23.05M | -29.71M | -24.37M | -11.92M | -19.73M | -13.23M | -6.98M |
| EBITDA Ratio | 0.00% | 0.00% | -2,679.40% | -1,881.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -87.04M | -56.76M | -41.43M | -28.54M | -33.45M | -30.75M | -32.35M | -27.52M | -21.09M | -20.92M | -13.87M | -8.80M |
| Operating Income Ratio | 0.00% | 0.00% | -2,761.73% | -1,902.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.63M | 2.31M | 815.00K | 1.02M | 548.00K | 7.63M | 2.47M | 1.89M | 9.04M | -4.50M | -4.31M | 1.04M |
| Income Before Tax | -81.41M | -54.45M | -40.61M | -27.52M | -32.90M | -23.12M | -29.88M | -25.63M | -20.95M | -25.42M | -18.18M | -7.76M |
| Income Before Tax Ratio | 0.00% | 0.00% | -2,707.40% | -1,834.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 147.00K | -24.00K | -2.00K | -3.00K | 20.00K | -157.00K | 4.35M | 152.00K | 31.00K | 149.00K | 0.00 |
| Net Income | -81.41M | -54.60M | -40.59M | -27.51M | -32.90M | -23.14M | -29.73M | -25.63M | -21.10M | -25.45M | -18.32M | -7.76M |
| Net Income Ratio | 0.00% | 0.00% | -2,705.80% | -1,834.27% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.98 | -4.82 | -4.73 | -4.64 | -14.57 | -16.36 | -32.45 | -27.29 | -12.37 | -21.45 | -24.62 | -10.42 |
| EPS Diluted | -3.98 | -4.82 | -4.73 | -4.64 | -14.57 | -16.05 | -32.35 | -27.29 | -12.37 | -21.45 | -24.62 | -10.42 |
| Weighted Avg Shares Out | 20.45M | 11.32M | 8.58M | 5.93M | 2.26M | 1.41M | 916.18K | 939.24K | 1.71M | 1.19M | 744.40K | 744.40K |
| Weighted Avg Shares Out (Dil) | 20.45M | 11.32M | 8.58M | 5.93M | 2.26M | 1.44M | 918.86K | 939.24K | 1.71M | 1.19M | 744.40K | 744.40K |
Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference
CAMBRIDGE, Mass. , Nov. 26, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.
Leap Therapeutics Reports Third Quarter 2024 Financial Results
CAMBRIDGE, Mass. , Nov. 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2024.
Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
CAMBRIDGE, Mass. , Sept. 30, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment of 188 patients has been completed in the randomized controlled Part B of...
3 Trending Biotech Penny Stocks
Biotech stocks are some of my favorite stocks to watch and invest in for a couple of reasons.
Leap Therapeutics Reports Second Quarter 2024 Financial Results
CAMBRIDGE, Mass. , Aug. 12, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2024.
Leap Therapeutics Reports First Quarter 2024 Financial Results
CAMBRIDGE, Mass. , May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2024.
Leap Therapeutics Announces $40 Million Private Placement
Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development program CAMBRIDGE, Mass. , April 11, 2024 /PRNewswire/ -- Leap...
Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks
Leap Therapeutics (LPTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
CAMBRIDGE, Mass. , March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2023.
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium
30% ORR and 93% DCR across heterogenous second-line CRC patients treated with DKN-01 plus bevacizumab and chemotherapy Subgroup analysis reveals greatest benefit in left-sided tumors, particularly rectal and rectosigmoid patients with 46% ORR, 100% DCR, and preliminary median PFS of...
Source: https://incomestatements.info
Category: Stock Reports